Member Info for RorkesDrift

They might have to at this rate

Individual companies could impose export embatgos.

My guess will be Gilead will sub contract but no one will jump up and down about price now or at least they can price discriminate between markets

Doggy100 thx as well

So 85% compacted to PCR and front previous posts the later is far from perfect.

Thanks for link as well - puts it into context

http://sdbiosensor.com/xe/product/7672

Apologies was trying to paste something else

Hindustan Times - Latest News
Home / Delhi News / Delhi to scale up rapid antigen testing in labs and hospitals
Delhi to scale up rapid antigen testing in labs and hospitals
The state health department issued these directions on Monday after the Indian Council of Medical Research (ICMR) released a fresh set of guidelines asking states to increase Covid-19 testing.
Coronavirus,ICMR,antigen testing
On Sunday, Delhi’s director general of health services (DGHS) issued an order asking all stakeholders to “strictly follow the advisory issued by the ICMR to increase the outreach of testing”.(Sanchit Khanna/HT PHOTO)
Updated: Jun 30, 2020 04:03 IST
By Sweta Goswami , Hindustan Times, New Delhi

The Delhi government has asked all hospitals and Covid-19 testing laboratories in the national Capital to start rapid antigen detection tests to scale up its ongoing process of identifying symptomatic patients and isolating them immediately. To further increase testing across the city, all district magistrates (DMs) have also been asked to set up at least seven more antigen testing centres in each of the 11 districts and double their daily testing target to 2,000, senior government officials said on Monday.

The state health department issued these directions on Monday after the Indian Council of Medical Research (ICMR) released a fresh set of guidelines asking states to increase Covid-19 testing. Even private hospitals and Covid-19 testing labs will have to provide the facility of rapid antigen testing, a health department official said on condition of anonymity.

Click here for full?Covid-19 coverage

So far, antigen detection tests were being administered to high-risk contacts and those living in containment zones. But with the latest directive, antigen detection tests will be administered to all.

“The Union ministry of home affairs has directed to double antigen tests in Delhi from the current target of 1,000 tests per day per district to 2,000. Delhi currently has 193 rapid antigen testing centres. Today, we have also asked all district magistrates to increase the number of their antigen testing centres to a total of 250, especially near the new containment zones. This means at least seven more antigen testing centres per district will have to be set up immediately. The health department has enough testing kits available for this purpose,” the official said. The Delhi government had recently procured at least 6 lakh antigen detection kits, which cost ?450 per kit as compared to ?2,400 for an RT-PCR test kit.

Rapid antigen detection tests are quicker (they take a maximum of 30 minutes to show results compared to an RT-PCR test’s 2-5 hours) and are non-confirmatory. This means that those who test positive through rapid antigen detection tests are considered “truly positive” for Covid-19 and do not have to undertake an RT-PCR test. But, those who test negative are then tested through the RT-PCR test for re-confirmation

Radish thanks for links. First one only published last week.

https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa797/5860439

Last years interim

"A proprietary pipeline of Affimer diagnostic assays aimed at accelerating licensing deals, continues to grow. The target of having two such assays completed by the end of 2019 is on track with a D-dimer and an estradiol assay nearing completion."

D-Dimer is a biomarker and correlates with clotting risk. Covid patients are at risk.

In other news

7 diagnostics evaluations including 4 with top 10 global in vitro diagnostic companies all of which could lead to licensing deals.
14 projects with pharma and biotech companies including 4 out of the top 10 large pharma.

TL. It was five and that was discussed pre-covid. I am not aware of what they have declared but scientific publications may give a glue.

Whilst we are all fixated on LFD, quantative diagnostics are of more interest. My guess and that is all it is, is

Troponin quantative bed side test
Flu LFD (preferably with covid 19)
E.coli et al for food preparation
Sepsis biomarkers
MRSA LFD

There are 100s they could go at - biomarkers are going to be a huge part of the future and technologies that are fast, accurate, portable and cost effective will make hay. Juries still out on what will win through and there will often be more than one way to sort the cat out.

Rapid and accurate SARS-CoV-2 diagnostic testing is essential for controlling the ongoing COVID-19 pandemic. The current gold standard for COVID-19 diagnosis is real-time RT-PCR detection of SARS-CoV-2 from nasopharyngeal swabs. Low sensitivity, exposure risks to healthcare workers, and global shortages of swabs and personal protective equipment, however, necessitate the validation of new diagnostic approaches. Saliva is a promising candidate for SARS-CoV-2 diagnostics because (1) collection is minimally invasive and can reliably be self-administered and (2) saliva has exhibited comparable sensitivity to nasopharyngeal swabs in detection of other respiratory pathogens, including endemic human coronaviruses, in previous studies. To validate the use of saliva for SARS-CoV-2 detection, we tested nasopharyngeal and saliva samples from confirmed COVID-19 patients and self-collected samples from healthcare workers on COVID-19 wards. When we compared SARS-CoV-2 detection from patient-matched nasopharyngeal and saliva samples, we found that saliva yielded greater detection sensitivity and consistency throughout the course of infection. Furthermore, we report less variability in self-sample collection of saliva. Taken together, our findings demonstrate that saliva is a viable and more sensitive alternative to nasopharyngeal swabs and could enable at-home self-administered sample collection for accurate large-scale SARS-CoV-2 testing.

Clearly not ignored.

I'll get my coat

What the Captain said - sentiment is swinging around but based on very little.

Not sure SP will be revenue based - the cash coming in if they get a test will weight it towards an asset value approach given that hopefully covid is not here for years and years to the same extent.

I started but it made my head hurt

Ah nope. That doesn't make any sense. I did point out you had shot yourself in the foot cause you were clearly more guilty of the accusations you were levelling at others.

You will notice the number of threads where I could have reported but they remain up. The only threads I have reported are where I see someone being either homophobic or racist.

Can we just post pubmed links to the papers - both +ve and -ve. People will need to DYOR on this one and horses mouth will help.

BAMS - proof of principle with RWD.

Lots of labs trained and know what to do

Question - whayelse could this approach target. I'm off to google proteinsvand mass spec

Bump

I have a confession ....

What happened to Orphidians admin post.?

Yep